Major firms forecast to suffer poor Q1 results

Published: 2011-04-18 07:00:00

Updated: 2011-04-18 07:00:00

Major Korean pharmaceutical companies are likely to see their first-quarter earnings worsen sharply, buffeted by dramatic changes in the business environment such as regulations by the government, conflicts among drug manufacturers, doctors and pharmacists and intense competition among generic dr...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK